Gabrielle Gainsborough

Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial

I. Pavord, A. Woodcock, P. Howarth, 2020, The Lancet. Respiratory medicine.